College of Pharmacy, Southwest University for Nationalities, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan 610041, PR China.
Crit Rev Oncol Hematol. 2017 Nov;119:50-58. doi: 10.1016/j.critrevonc.2017.09.016. Epub 2017 Oct 3.
A meta-analysis was conducted to systematically review the risk of hand-foot skin reaction (HFSR) with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in patients with cancer. The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with VEGFR-TKIs were retrieved and the systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published till May 2017. Twenty-one RCTs and 9552 patients were included. The current analysis suggested that the use of VEGFR-TKIs increased the risk of all-grade HFSR (7.04;95%CI, 5.33-9.30;p<0.00001) and high-grade (≥grade 3) HFSR (21.62;95%CI, 15.19-30.78;p<0.00001). On subgroup analyses, the risk ratio (RR) of all-grade HFSR varies significantly according to cancer type, whereas the RR of high-grade HFSR did not. The risk of all-grade and high-grade HFSR did not affect by drug types, treatment line, median age and treatment duration.
一项荟萃分析系统地回顾了血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）治疗癌症患者的手足皮肤反应（HFSR）风险。检索了癌症患者接受 VEGFR-TKI 治疗的随机对照试验（RCT）的相关研究，并进行了系统评价。检索了截至 2017 年 5 月的 EMBASE、MEDLINE 和 PubMed 中的文章。纳入了 21 项 RCT 和 9552 例患者。目前的分析表明，使用 VEGFR-TKI 增加了所有级别 HFSR（7.04；95%CI，5.33-9.30；p<0.00001）和高级别（≥3 级）HFSR（21.62；95%CI，15.19-30.78；p<0.00001）的风险。亚组分析显示，所有级别 HFSR 的风险比（RR）根据癌症类型而有显著差异，而高级别 HFSR 的 RR 则没有。所有级别和高级别 HFSR 的风险不受药物类型、治疗线、中位年龄和治疗持续时间的影响。
